• AT-5214 is a single isomer of mecamylamine that inhibits α3β4 nicotinic receptors and is a potent nicotine acetylcholine antagonist
  • Primary hyperhidrosis is associated with a selective increase in sympathetic activity
  • AT-5214 will inhibit primary hyperhidrosis in all localizations
  • Rapid and cost effective development path in primary hyperhidrosis. Over 2,900 patients have been treated with AT-5214 for other indications with a well and favorable characterized and favorable safety profile
  • Currently, Atacama successfully completed is testing of AT-5214 in a Phase 2 clinical trial for palmar hyperhidrosis.
  • Strong support from KOLs and the key hyperhidrosis patient advocacy group